Skip to content

Study of Tomotherapy HD in Medulloblastoma

Study of Tomotherapy HD in Medulloblastoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03675230
Enrollment
220
Registered
2018-09-18
Start date
2018-01-12
Completion date
2020-06-30
Last updated
2018-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medulloblastoma

Keywords

TOMO irradiation

Brief summary

The aim of the study was to improve local control and long-term survival in children with medulloblastoma, reduce the side effects of treatment and improve quality of life.

Detailed description

The technical advantages of Tomotherapy HD in the radiotherapy of children medulloblastoma (advantages in clinical operation and physics) were transformed into clinical advantages, and the possible mechanisms were explored.

Interventions

DEVICETomotherapy HD

Patients with Medulloblastoma receiving Tomotherapy

DEVICE3DCRT

Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
3 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* The patient was diagnosed as myeloblastoma by surgical pathology with definite pathological classification. MRI of the head and spinal cord before and after operation, with definite staging; Radiotherapy was performed within 28 days after surgery.

Exclusion criteria

* Previous radiotherapy in the whole brain, whole spinal cord or primary focus; Postoperative radiotherapy for more than 28 days.

Design outcomes

Primary

MeasureTime frameDescription
QoL(quality of life)2 yearsChanges in quality of life were assessed by EORTC QLQ-C30

Secondary

MeasureTime frameDescription
PFS (progression free survival)2 yearsfrom the first day of therapy to the date of disease progression or death from any cause, whichever was first (according the criterion of RECIST 1.1 ).
OS (overall survival)2 yearsfrom the first day of therapy to death or last follow-up

Countries

China

Contacts

Primary Contactchuanying zhu, MD
zhuchuanying@xinhuamed.com.cn13795327309

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026